United StatesBreaking News

enGene Therapeutics (NASDAQ:ENGN) announced its financial results for the second quarter ended April 30, 2026, alongside updates on its clinical development pipeline.

Elicio Therapeutics (NASDAQ:ELTX) announced results from its randomized Phase 2 AMPLIFY-7P trial evaluating ELI-002 7P in patients with mKRAS-driven pancreatic ductal adenocarcinoma.

Precigen (NASDAQ:PGEN) has been granted FDA orphan drug exclusivity for its product PAPZIMEOS, used to treat adult recurrent respiratory papillomatosis.

Salesforce (NYSE:CRM) announced it will acquire Fin, formerly known as Intercom, for approximately $3.6 billion to accelerate its position in the autonomous agent market.

Humacyte (NASDAQ:HUMA) announced that its Phase 3 V012 study met its primary superiority endpoint, showing the company’s acellular tissue engineered vessel (ATEV) significantly reduces time spent on dialysis catheters.

TuHURA Biosciences (NASDAQ:HURA) announced today that it has submitted an Investigational New Drug application to the U.S. Food and Drug Administration to advance its TBS-2025 therapy.

Paranovus Entertainment Technology (NASDAQ:PAVS) executed a non-binding letter of intent to acquire Jabanero for a proposed all-cash purchase price of $15 million to $20 million.

Jerash Holdings (NASDAQ:JRSH) reported record full-year fiscal 2026 revenue of $166.3 million following a 46.6% surge in fourth-quarter sales.

Alkermes plc (NASDAQ:ALKS) announced that its investigational oral medication, alixorexton, was granted orphan drug designations by regulatory authorities in the United States and Europe for rare sleep disorders.

The US and Iran said they reached an interim agreement to reopen the Strait of Hormuz, setting the stage for 60 days of negotiations on the fate of Tehran's nuclear program. Officials from the two countries will meet in Switzerland on June 19 to formally sign the agreement. Bloomberg's Tyler Kendall reports.

IREN (NASDAQ:IREN), a leading vertically integrated AI Cloud infrastructure provider, today announced the formal completion of its acquisition of Ingenostrum, S.L., widely known as Nostrum Group.

Coda Octopus Group (NASDAQ:CODA) reported its fiscal second-quarter 2026 financial results for the period ended April 30, 2026.